SOURCE: NeuroInvestment

January 16, 2008 09:00 ET

CNS Field Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - January 16, 2008) - NI Research has released the January issue of NeuroInvestment, which includes a review of the past year's achievements, both for better and for worse, and an assessment of prospects for 2008.

Among the topics covered:

1) The Best and the Worst Big Pharma Partnering Performance Awards for 2007

2) The Best CNS licensing deals of 2007, including reviews of partnerships entered into by Targacept and GSK, Ceregene and Genzyme, Addex and Merck, BioMS and Lilly.

3) NI's annual CEO of the Year award. Finalists included CEO's from Evotec, XenoPort, Ceregene, and Corcept.

4) Our annual review of CNS IPO performance.

5) The biggest CNS disappointments of 2007. Coverage includes Neurochem, Renovis, Vanda's iloperidone program, and Cephalon's promotion of Vivitrol.

6) Pointed commentary is included regarding Shire and Vyvanse, Medivation and Dimebon, Noven's acquisition of JDS Pharmaceuticals, and the demise of Neurocrine's (NASDAQ: NBIX) indiplon.

7) Succinct summaries of the status and prospects of 73 CNS-oriented companies. This ranges from major companies like Cephalon, Shire, and Elan; through midsize companies like Evotec and Acadia Pharmaceuticals, to micro companies like Memory Pharmaceuticals, Torrey Pines Therapeutics (NASDAQ: TPTX), and Cortex Pharmaceuticals (AMEX: COR).

8) Anticipated 2008 events, led by Elan/Wyeth's AAB-001 Phase II data.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1600, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three month trial subscription is US$600.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, and the Private CNS Company Review since 2003. In 2007 NI Research launched an annual compendium of all neuro-oriented R&D programs organized by disorder, CNS 2007, as well as an annual review of the Alzheimer's therapeutics area, Alzheimer's 2008. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

Contact Information